The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. BridgeBio Pharma Inc shares valued at $149,350,000 were sold by KKR Genetic Disorder L.P. on Sep 13 ’24. At $25.75 per share, KKR Genetic Disorder L.P. sold 5,800,000 shares. The insider’s holdings dropped to 25,260,971 shares worth approximately $630.51 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, KKR Genetic Disorder L.P. purchased 5,800,000 shares, netting a total of over 156,310,000 in proceeds.
Before that, Kumar Neil had sold 27,389 shares from its account. In a trade valued at $676,256, the Chief Executive Officer traded BridgeBio Pharma Inc shares for $24.69 each. Upon closing the transaction, the insider’s holdings decreased to 27,389 shares, worth approximately $122.24 million.
As published in their initiating research note from Oppenheimer on October 03, 2024, BridgeBio Pharma Inc [BBIO] has been a Perform. Analysts at Piper Sandler started covering the stock with ‘”an Overweight”‘ outlook in a report released in early September. Earlier on January 31, 2024, BMO Capital Markets initiated its rating. Their recommendation was “a Market perform” for BBIO stock.
Analyzing BBIO Stock Performance
During the last five days, there has been a drop of approximately -2.61%. Over the course of the year, BridgeBio Pharma Inc shares have dropped approximately -38.17%. Shares of the company reached a 52-week high of $41.04 on 02/15/24 and a 52-week low of $21.62 on 06/24/24. A 50-day SMA is recorded $25.92, while a 200-day SMA reached $29.22. Nevertheless, trading volume fell to 2.34 million shares from 2.64 million shares the previous day.
Support And Resistance Levels for BridgeBio Pharma Inc (BBIO)
According to the 24-hour chart, there is a support level at 23.46, which, if violated, would cause prices to drop to 21.95. In the upper region, resistance lies at 25.76. The next price resistance is at 26.55. RSI (Relative Strength Index) is 46.37 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.52, which suggests the price will decrease in the coming days. Percent R is at 44.40%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
